Clinical trial
Phase III Study to Determine the Efficacy of Durvalumab in Combination With…
NCT04385368 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT04385368 |
|---|---|
| Title | Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) |
| Official title | A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MERMAID-1) |
| Acronym | MERMAID-1 |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug, Other |
| Interventions | Durvalumab + SoC chemotherapy, Placebo + SoC chemotherapy |
| Enrollment | 89 |
| Start date | Jul 17, 2020 |
| Primary completion | Aug 31, 2023 |
| Completion | Aug 31, 2023 |
| First posted | May 12, 2020 |
| Last update posted | Aug 30, 2024 |
| Countries | Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Czechia, Denmark, France, Germany, Greece, Hong Kong and 21 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: